Abstract
Becton Dickinson will report fiscal results on February 09, 2026 Pre-Market; this preview consolidates recent financial data, current-quarter forecasts, and institutional perspectives to frame revenue, margin, and EPS expectations alongside segment drivers and risks.
Market Forecast
Consensus points to Becton Dickinson’s current-quarter revenue estimate of USD 5.15 billion, an adjusted EPS estimate of USD 2.85, and EBIT of USD 1.09 billion, with year-over-year changes of 1.10% for revenue, -4.46% for adjusted EPS, and -3.91% for EBIT. Quarter-specific gross profit margin and net profit margin forecasts were not disclosed; last quarter’s gross margin was 47.51% and net margin was 8.37%, providing a directional backdrop for expectations. The company’s core businesses are forecast to remain stable, with incremental growth concentrated in consumables and device placements that support recurring revenue. The segment with the strongest near-term promise is “医疗” (Medical), given its scale and recurring consumables profile, though current-quarter segment revenue and YoY growth details were not provided.
Last Quarter Review
Becton Dickinson’s prior quarter delivered revenue of USD 5.89 billion, a gross profit margin of 47.51%, GAAP net profit attributable to the parent company of USD 0.49 billion, a net profit margin of 8.37%, and adjusted EPS of USD 3.96, with year-over-year growth of 8.33% for revenue and 3.94% for adjusted EPS. A notable highlight was EBIT of USD 1.52 billion, which modestly exceeded market expectations, reflecting disciplined cost management and healthy product mix. Main business contributions were led by “医疗” (Medical) at USD 11.46 billion, “介入” (Interventional) at USD 5.22 billion, and “生命科学” (Life Sciences) at USD 5.17 billion, though a quarter-specific YoY breakdown for these segments was not disclosed.
Current Quarter Outlook (with major analytical insights)
Main Business: Medical
Medical remains Becton Dickinson’s largest franchise, benefiting from a deep installed base of infusion systems, IV access products, and medication delivery consumables that underpin recurring revenue. The quarter is likely to depend on utilization stability across hospital and ambulatory settings, where procedure volumes have trended steady. Pricing discipline and product mix should help protect margins, even as labor and logistics costs fluctuate, but the 47.51% gross margin in the prior quarter establishes a reasonable benchmark. Upside in Medical could come from incremental placements and the conversion of accounts to premium portfolios, yet currency and regional demand variability can temper reported growth. Given the forecast of USD 5.15 billion in consolidated revenue and USD 1.09 billion EBIT, stable Medical consumables should anchor results and contribute to resilience despite a modest EPS decline expected year-over-year.
Most Promising Business: Interventional
Interventional is well positioned to add growth through newer product lines and continued procedural adoption in areas such as vascular access management and oncology-related interventions. The franchise benefits from product innovation cycles that can enhance value capture per procedure while expanding addressable use cases. Mix shifts toward higher-complexity devices may support margin preservation, though manufacturing and supply chain execution must remain tight to avoid cost pressure. Given the consolidated forecast that anticipates a slight revenue increase and modest margin compression at the EPS level, Interventional could offset softer areas by leaning on differentiated devices and gradually improving utilization rates. Near-term execution in commercial channels and stable procurement patterns at health systems will matter for translating innovation into realized revenue.
Stock Price Drivers This Quarter
Investor focus will likely center on the relationship between revenue growth and margin sustainability, particularly whether management can convert stable demand into balanced EPS performance amid the forecasted year-over-year decline. Any commentary on pricing, supply continuity, and backlog normalization may shape sentiment, as the last quarter’s gross margin of 47.51% sets expectations for operational consistency. Updates on product launches or portfolio rationalization could influence perceptions of medium-term growth visibility, especially across Interventional and premium consumables in Medical. Guidance around the trajectory for EBIT and adjusted EPS relative to cost initiatives will be a key signal for the stock, as investors weigh momentum against potential cost or currency headwinds.
Analyst Opinions
Across recent institutional commentary, the majority view is cautiously positive ahead of the print, emphasizing defensive characteristics and recurring consumables that can underpin stable revenue while acknowledging pressure on EPS growth. Analysts have highlighted the prior quarter’s EBIT outperformance versus estimates as an indicator of operational discipline, and previews point to consensus for USD 5.15 billion of revenue and USD 2.85 of adjusted EPS this quarter. Some firms suggest that enduring demand in Medical and improving mix in Interventional should support top-line stability, while EPS faces headwinds from investment, inflation, and currency. The bullish camp argues that steady revenue, diversified segments, and consumables exposure present a favorable risk-reward into the event, and that execution on margin initiatives can mitigate EPS softness even if YoY declines persist near-term. Overall, the aggregated stance leans constructive, with emphasis on stability and measured growth drivers rather than aggressive upside calls.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments